Certain aryl substituted pyrrolopyrazines; a new class of gaba b

Details Certain aryl substituted pyrrolopyrazines; a new class of gaba b Certain aryl substituted pyrrolopyrazines; a new class of gaba b

1995-05-12

1997-02-25

Bernhardt, Emily

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

540578, 544230, 544234, C07D48704, C07D48710, C07D48714, C07D48720

Patent

active

056060599

DESCRIPTION:

BRIEF SUMMARY
BACKGROUND OF THE INVENTION

This application is a continuation in part of U.S. Patent Application Ser. No. 07/975,409, filed Nov. 12, 1992.
1. Field of the Invention
This invention relates to certain aryl substituted pyrrolopyrazines which selectively bind to GABAa receptors. This invention also relates to pharmaceutical compositions comprising such compounds. It further relates to the use of such compounds in treating anxiety, sleep and seizure disorders, and overdoses of benzodiazepine-type drugs, and enhancing alertness. The interaction of pyrrolopyrazines of the invention with a GABA binding site, the benzodiazepines (BDZ) receptor, is described. This interaction results in the pharmacological activities of these compounds.
2. Description of the Related Art
.gamma.-Aminobutyric acid (GABA) is regarded as one of the major inhibitory amino acid transmitters in the mammalian brain. Over 30 years have elapsed since its presence in the brain was demonstrated (Roberts & Frankel, J. Biol. Chem. 187: 55-63, 1950; Udenfriend. J. Biol. Chem. 187: 65-69, 1950). Since that time an enormous effort has been devoted to implicating GABA in the etiology of seizure disorders, sleep, anxiety and cognition (Tallman and Gallager, Ann. Rev. Neuroscience 8: 21-44, 1985). Widely, although unequally, distributed through the mammalian brain, GABA is said to be a transmitter at approximately 30% of the synapses in the brain. In most regions of the brain, GABA is associated with local inhibitory neurons and only in two regions is GABA associated with longer projections. GABA mediates many of its actions through a complex of proteins localized both on cell bodies and nerve endings; these are called GABAa receptors. Postsynaptic responses to GABA are mediated through alterations in chloride conductance that generally. although not invariably, lead to hyperpolarization of the cell. Recent investigations have indicated that the complex of proteins associated with postsynaptic GABA responses is a major site of action for a number of structurally unrelated compounds capable of modifying postsynaptic responses to GABA. Depending on the mode of interaction, these compounds are capable of producing a spectrum of activities (either sedative, anxiolytic and anticonvulsant, or wakefulness, seizures, and anxiety).
1.4-Benzodiazepines continue to be among the most widely used drugs in the world. Principal among the benzodiazepines marketed are chlordiazepoxide, diazepam, flurazepam, and triazolam. These compounds are widely used as anxiolytics, sedative-hypnotics, muscle relaxants, and anticonvulsants. A number of these compounds are extremely potent drugs; such potency indicates a site of action with a high affinity and specificity for individual receptors. Early electrophysiological studies indicated that a major action of benzodiazepines was enhancement of GABAergic inhibition. The benzodiazepines were capable of enhancing presynaptic inhibition of a monosynaptic ventral root reflex, a GABA-mediated event (Schmidt et al., 1967, Arch. Exp. Path. Pharmakol. 258: 69-82). All subsequent electrophysiological studies (reviewed in Tallman et al. 1980, Science 207:274-81, Haefley et al., 1981, Handb. Exptl. Pharmacol. 33:95-102) have generally confirmed this finding, and by the mid-1970s, there was a general consensus among electrophysiologists that the benzodiazepines could enhance the actions of GABA.
With the discovery of the "receptor" for the benzodiazepines and the subsequent definition of the nature of the interaction between GABA and the benzodiazepines, it appears that the behaviorally important interactions of the benzodiazepines with different neurotransmitter systems are due in a large pan to the enhanced ability of GABA itself to modify these systems. Each modified system, in turn, may be associated with the expression of a behavior.
Studies on the mechanistic nature of these interactions depended on the demonstration of a high-affinity benzodiazepine binding site (receptor). Such a receptor is present in the CNS of all vertebrates ph

REFERENCES:
patent: 3455943 (1969-07-01), Remers et al.
patent: 4435403 (1984-07-01), Braestrup et al.
patent: 4596808 (1986-06-01), Braestrup et al.
patent: 4623649 (1986-11-01), Huth et al.
patent: 4719210 (1988-01-01), Seidelmann et al.
patent: 5286860 (1994-02-01), Blum et al.
Biere et al, Liebigs Ann. Chem. pp. 1749-1764 (1986).

Affiliated with

Also associated with

Rating

Certain aryl substituted pyrrolopyrazines; a new class of gaba b does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Certain aryl substituted pyrrolopyrazines; a new class of gaba b, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Certain aryl substituted pyrrolopyrazines; a new class of gaba b will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1975079